[go: up one dir, main page]

HRP940279B1 - IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS - Google Patents

IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Info

Publication number
HRP940279B1
HRP940279B1 HR940279A HRP940279A HRP940279B1 HR P940279 B1 HRP940279 B1 HR P940279B1 HR 940279 A HR940279 A HR 940279A HR P940279 A HRP940279 A HR P940279A HR P940279 B1 HRP940279 B1 HR P940279B1
Authority
HR
Croatia
Prior art keywords
antigens
prevention
preparation
treatment
recombinant methods
Prior art date
Application number
HR940279A
Other languages
English (en)
Inventor
Livey Ian
Crowe Brian
Dorner Friedrich
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of HRP940279A2 publication Critical patent/HRP940279A2/hr
Publication of HRP940279B1 publication Critical patent/HRP940279B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HR940279A 1993-04-29 1994-04-29 IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS HRP940279B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29

Publications (2)

Publication Number Publication Date
HRP940279A2 HRP940279A2 (en) 1997-10-31
HRP940279B1 true HRP940279B1 (en) 2000-12-31

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
HR940279A HRP940279B1 (en) 1993-04-29 1994-04-29 IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Country Status (16)

Country Link
EP (1) EP0701612B1 (no)
JP (1) JPH08509371A (no)
AT (1) ATE162550T1 (no)
AU (1) AU683260B2 (no)
CA (1) CA2161534A1 (no)
CZ (1) CZ289212B6 (no)
DE (1) DE69408135T2 (no)
DK (1) DK0701612T3 (no)
ES (1) ES2114687T3 (no)
FI (1) FI955150A (no)
HR (1) HRP940279B1 (no)
HU (1) HU217024B (no)
NO (1) NO954318L (no)
PL (1) PL178775B1 (no)
SK (1) SK279968B6 (no)
WO (1) WO1994025596A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
EP0896583B1 (en) * 1996-05-02 2003-02-05 Dako A/S Use of peptide fragments derived from osp-c for diagnostic methods
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
DE69938183T2 (de) 1998-07-31 2009-02-19 Gundersen Lutheran Medical Foundation, Inc., La Crosse Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
DK1194559T3 (da) 1999-06-18 2007-02-05 Univ New York State Res Found Grupper af Borrelia burgdorferi, som forårsager Lyme sygdom hos mennesker
AU2001285049A1 (en) 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
EP1957520A4 (en) * 2005-11-29 2009-05-27 Univ Virginia Commonwealth POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN
CN101573135B (zh) * 2006-11-03 2013-06-12 先灵-普劳有限公司 犬莱姆病疫苗
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
WO2025015077A1 (en) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
PL178775B1 (pl) 2000-06-30
NO954318D0 (no) 1995-10-27
DE69408135D1 (de) 1998-02-26
FI955150A0 (fi) 1995-10-27
HU217024B (hu) 1999-11-29
AU6722994A (en) 1994-11-21
CA2161534A1 (en) 1994-11-10
HU9502002D0 (en) 1995-08-28
EP0701612A1 (en) 1996-03-20
DE69408135T2 (de) 1998-06-10
CZ283995A3 (en) 1996-03-13
SK134195A3 (en) 1996-05-08
JPH08509371A (ja) 1996-10-08
ES2114687T3 (es) 1998-06-01
EP0701612B1 (en) 1998-01-21
AU683260B2 (en) 1997-11-06
HRP940279A2 (en) 1997-10-31
PL311301A1 (en) 1996-02-05
SK279968B6 (sk) 1999-06-11
DK0701612T3 (da) 1998-09-21
CZ289212B6 (cs) 2001-12-12
NO954318L (no) 1995-12-29
ATE162550T1 (de) 1998-02-15
FI955150A (fi) 1995-12-28
HUT72923A (en) 1996-06-28
WO1994025596A3 (en) 1994-12-22
WO1994025596A2 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
HRP940279B1 (en) IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
CA2001328A1 (en) Borrelia antigen
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
DK0598816T3 (da) Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
ZA883954B (en) Avirulent microbes and uses therefor
EP1630229A3 (en) Melanoma antigens
PL325373A1 (en) Compounds and methods useful in tuberculosos immunotherapy and diagnostics
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
DE69533594D1 (de) Präparate und verfahren zum auslösen von ctl-immunität
DK0555276T3 (da) Immunogene komplekser, især iscomer
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
ES8800052A1 (es) Un procedimiento para preparar una proteina de superficie antigenica de anaplasma marginale
EP1020516A3 (en) Leptospira vaccine antigens for the prevention of leptospirosis
DE69615537D1 (en) Helicobacter pylori antigen
WO1999015692A3 (en) Dengue virus antigens and treatment of dengue fever
HUP0002752A2 (hu) Egy szekréciós vektor alkalmazása termékenység-szabályozásra orális vakcinálással
BR9707667A (pt) Complexos imunogênicos na forma de iscoms.
MX9700215A (es) Proteinas y vacunas de helicobacter.
CA2347278A1 (en) Vaccine based on attenuated haemophilus somnus
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAXTER AKTIENGESELLSCHAFT, AT

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040406

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20050430